Oklahoma State University Center for Health Sciences
Oklahoma State University Center for Health Sciences

News Alert:

Pharmacology and Physiology

Faculty and Staff

David R. Wallace, Ph.D.David R. Wallace, Ph.D.
Assistant Dean for Research
Director for Integrative Neuroscience
Professor of Pharmacology

david.wallace@okstate.edu
918-561-1407
918-561-5784 lab
918-561-5729 fax

Education | Professional Experience | Service & Contribution | Professional Societies | Extramural Funding | Publications | Instructional Activities | Research Interests | Biographical Information

 

Education

1992-1996
Postdoctoral Fellow (Pharmacology)
University of Kentucky
Lexington, KY

1990-1992
Postdoctoral Fellow (Pharmacology)
University of Colorado Health Science Center
Denver, CO

1991
Ph.D. (Pharmaceutical Science)
University of Florida
Gainesville, FL

1984
B.S. (Biomedical Science)
Western Michigan University
Kalamazoo, MI

Professional Experience

2007-present
Professor of Pharmacology, OSU-CHS, Tulsa, OK

2006-present
Assistant Dean for Research, OSU-CHS, Tulsa, OK

2005-present
Adjunct Associate Professor, Toxicology, OSU Veternary Health Science Center, Stillwater, OK

2004-present
Associate Professor, Forensic Science, OSU Center for Health Sciences (OSU-CHS), Tulsa, OK

2001-2007
Associate Professor, Pharmacology & Physiology, OSU-CHS

1997-2001
Adjunct Assistant Professor, Health Sciences and Nursing Education, Rogers State University, Claremore, OK

1996-2001
Assistant Professor, Pharmacology & Physiology, OSU-CHS

Service & Contribution

  • Editorial Board, Journal of Clinical Toxicology
  • Member of OKBio Postdoctoral Fellow Training Committee and Programming Committee
  • Faculty Advisor, for OSU-CHS Student Osteopathic Research Association (SORA), 2007-2008
  • Member, Biotechnology Advisory Board, Tulsa, Oklahoma, 2006-present
  • Ex Officio Member, Institutional Biosafety Committee, OSU-CHS, 2009-present
  • Chair, Chemical Hygiene and Radiation Use Committee, OSU-CHS, 2009-present
  • Founding member and Advisory Board member, Tulsa Area Bioscience Education and Research Consortium, 2009-present
  • Chair, Research Committee, OSU-CHS, 2005-2006
  • Past-President, Faculty Senate, OSU-CHS, 2005-2006
  • President, Faculty Senate, OSU-CHS, 2004-2005
  • Vice-Chair, Biomedical Science Section of the Oklahoma Academy of Sciences, 2003-2004
  • President-Elect, Faculty Senate, OSU-CHS, 2003-2004
  • Member, Institutional Animal Use and Care Committee, OSU-CHS, 2002-2003
  • Secretary, Faculty Senate, OSU-CHS, 2002-2003
  • Member, Faculty Senate, OSU-CHS, 2001-2003
  • Member, Biomedical Science Graduate Committee, OSU-CHS, 2001-present
  • Member, Hazardous Materials and Equipment Committee, OSU-CHS, 2001-present
  • Member, Budget and Benefits Committee, OSU-CHS, 2001-2002
  • Chair, Research Committee, OSU-CHS, 2001-present
  • Member, Pharmacology Faculty Search Committee, OSU-CHS, 2000-2001
  • Chair, Biomedical Science Section of the Oklahoma Academy of Sciences, 2000-2003
  • Secretary, Faculty Senate, OSU-CHS, 2000-2001
  • Member, Institutional Review Board, OSU-CHS, 2000-2002
  • Vice-Chair, Biomedical Science Section of the Oklahoma Academy of Sciences, 1999-2000
  • Coordinator, Biomedical Science Seminar Series, OSU-CHS, 1999-2000
  • Sargent-At-Arms, Faculty Senate, OSU-CHS, 1999-2000
  • Member, Physiology Faculty Search Committee, OSU-CHS, 1998-1999
  • Member, Radiation Safety Committee, OSU-CHS, 1998-present
  • Member, Research Committee, OSU-CHS, 1997-2001
  • Member, Curriculum Committee, OSU-CHS, 1997-2000
  • Member, Pharmacology Faculty Search Committee, OSU-CHS, 1997
  • Reviewer, “Biomedical Sciences Section”, Oklahoma Academy of Sciences, 1996-1997
  • Consultant, Williams and Associates, Memphis, TN, 1993

Professional Societies

  • Society for Neuroscience
  • International Brain Research Organization
  • American Society for Neurochemistry
  • American Society for Pharmacology and Experimental Therapeutics
  • Experimental Biology
  • Oklahoma Academy of Science
  • International Society for Neurotoxicology
  • Society for Toxicology

Extramural Funding

Current Funding:

  • Intramural Grant OSU-CHS, Title: “Heavy metal toxicity on cellular function”, (PI), $7,500

    Previous Funding:

    • Intramural Grant from the Interdisciplinary Biomedical Engineering Research Initiative, Title: “Acoustic Analysis of Whole Blood Using Micro-Resonators”, (co-PI) $4,000, 2011-2012
    • Oklahoma Tobacco Research Center Seed Grant, Title: “Development of an organocatalytic and enantioselective C-C bond forming method for the synthesis of smoking cessation agents”, (co-PI; 15% effort), $50,000, 2011-2012
    • OSU Interdisciplinary Creative Planning Grant Program, Title: “Interdisciplinary Biomedical Research Initiative: A joint program between OSU-Tulsa, CHS, and Stillwater”, (PI), $20,926, 2011-2012.
    • OSU Interdisciplinary Creative Planning Grant Program, Title: “Interdisciplinary Program in Toxicology”, (PI at Center for Health Sciences), 28,353, 2011-2012.
    • Characterization of the D3-preferring agonist, Pramipexole in rat striatum and nucleus accumbens, Pharmacia-Upjohn, $6,000, 1996-1997
    • Functional Evolution of Opioid Receptors, NIH/NIDA DA12448 (Co-Investigator, 5% effort), $75,000, 1999-2000
    • Delta Opioid Attenuation of Oxidative Stress in SK-N-SH cells., American Society of Pharmacology and Experimental Therapeutics (ASPET), SURF Award, $2,500, 2001
    • Gender Differences in gp120 and Tat Neurotoxicity, BRIN Undergraduate Fellowship, $1,500, 2003
    • Functional Evolution of Opioid Receptors NIH/NIDA DA12448, (Co-Investigator, 5% effort), $146,500, 2002-2003
    • Gender differences in gp120 and Tat neurotoxicity, Oklahoma EPScoR BRIN fellowship, $1,500, 2003
    • HIV/Cocaine Neurotoxicity in Females, NIH/NIDA DA13137 (PI, 25% effort, subcontract through University of Kentucky; Dr. Rosemarie Booze, PI), $198,000, 1999-2004
    • HIV/Cocaine Neurotoxicity in Females, NIH/NIDA DA13137-2  (PI, 25% effort, subcontract through University of South Carolina; Dr. Rosemarie Booze, PI), $240,000, 2005-2010
    • Dopamine-Chemokine Interactions: Target for Heavy Metals Toxicity, NIH/NIOSH CCT610417 (PI, 25% effort, subcontract through University of Texas-Houston and the Southwest Center for Occupational and Environmental Health SWCOEH; $7,992 total cost) 2009-2010


    Representative Publications & Presentations

    J. Zhu, C.F. Mactutus, D.R. Wallace and R.M. Booze (2009) HIV-1 Tat protein-induced rapid and reversible decrease in [3H] dopamine uptake: dissociation of [3H] dopamine uptake and [3H] WIN35,428 binding in rat striatal synaptosomes.  J. Pharmacol. Exp. Therap. 329:1071-1083.

    J.T. Curtis, A.N. Hood, Y. Chen, G.P. Cobb and D.R. Wallace (2010) Chronic metals ingestion by prairie voles produces sex-specific deficits in social behavior: An animal model of autism.  Behav Brain Res (http://www.sciencedirect.com/scidirimg/clear.gifdoi:10.1016/j.bbr.2010.04.028)

    R. Dawson Jr. and D.R. Wallace. (1990). Neural renal interactions in the hypertension induced by papillary necrosis: Role of dietary NaCl intake. Pharmacol., 40:42-53.

    R. Dawson Jr. and D.R. Wallace, and M.J. King. (1990). Monoamine and amino acid content in brain regions of the Brattleboro rat. Neurochem. Res., 15:755-761.

    D.R. Wallace and R. Dawson Jr. (1990). Decreased plasma taurine content in aged rats. Gerontol., 36:19-27.

    R.J. Ulshafer, D.M. Sherry, R. Dawson Jr., and D.R. Wallace. (1990). Excitatory amino acid involvement in retinal degeneration. Brain Res., 531:350-354.

    D.R. Wallace and R. Dawson Jr. (1990). Effect of age and monosodium L glutamate treatment on neurotransmitter content in brain regions from male Fischer 344 rats. Neurochem. Res., 15:889-898.

    R. Dawson Jr. and D.R. Wallace. (1992) Taurine content in tissues from aged Fischer 344 rats. AGE, 15:73-81.

    D.R. Wallace and R. Dawson Jr. (1992). Ammonia regulation of phosphate activated glutaminase displays regional variation and impairment in the brain of aged rats. Neurochem. Res., 17:1113-1122.

    R. Dawson Jr. and D.R. Wallace. (1992) Kainic acid induced seizures in aged rats: Neurochemical Correlates. Brain Res. Bull., 29:459-468.

    R. Dawson Jr. and D.R. Wallace. (1993) Regulation of phosphate activated glutaminase (PAG) by glutamate analogues. Neurochem. Res., 12:125-132.

    D.R. Wallace and R. Dawson Jr. (1993) Regional regulations of phosphate activated glutaminase in rat brain by calcium and phosphate: Impairment in aged rats and implication for the existence of isozymes. Neurochem. Res., 18:1271-1279.

    D.R. Wallace, D.T. Muskardin and N.R. Zahniser. (1994) Pharmacological characterization of [3H] idazoxan, [3H] RX821002 and para [125I] iodoclonidine binding to alpha2 adrenoceptors in rat cerebral cortex membranes. Eur. J. Pharmacol., 258:67-76.

    D.R. Wallace and R. Dawson Jr. (1994) Effect of the aging process on kinetics and activity of phosphate activated glutaminase from various brain regions of adult and aged Fischer 344 rats. AGE, 17:59-63.

    R.M. Booze and D.R. Wallace. (1995) Dopamine D2 and D3 receptors in the rat striatum and nucleus accumbens: Use of 7-OH-DPAT and [125I]Iodosulpride. Synapse, 19:1-13.

    D.R. Wallace and R.M. Booze. (1995) Identification of D3 and sigma receptors in the rat striatum and nucleus accumbens using (+/-)-7-hydroxy-N,N-di-n-[3H]propyl-2-aminotetralin and carbetapentane. J. Neurochem., 64:700-710.

    D.R. Wallace and R.M. Booze. (1995) Pramipexole, a D3-selective agonist that lacks sigma interactions in the rat brain. Neurosci. Res. Comm. 17:177-183.

    D.R. Wallace, C.F. Mactutus and R.M. Booze. (1996) Repeated intravenous cocaine administration: Locomotor activity and dopamine D2/D3 receptors. Synapse 23:152-163.

    D.R. Wallace and R.M. Booze. (1996). Dopamine D3 receptor density elevation in aged Fischer-344 X Brown Norway (F1) rats. Eur. J. Pharmacol., 308:283-285.

    D.R. Wallace and R.M. Booze. (1997) Upregulation of (+)-7-hydroxy-N,N-di-n-[3H]propylaminotetralin binding following intracerebroventricular administration of a nitric oxide generator. Neurochem. Res. 22:163-170.

    R.M. Booze, A.F. Lehner, D.R. Wallace and C.F. Mactutus. (1997) Dose response cocaine pharmacokinetics and metabolite profile following intravenous administration and arterial sampling in unanesthetized freely moving male rats. Neurotoxicol. Teratol. 19:7-15.

    P.C. Bickford, C.E. Adams, S.J. Boyson, P. Curella, G.A. Gerhardt, C. Heron, G.O. Ivy, A.M.L.Y. Lin, M.P. Murphy, K. Poth, D.R. Wallace, D.A. Young, N.R. Zahniser, G.M. Rose. (1997). Long term treatment of male F344 rats with deprenyl: Assessment of effects on longevity, behavior, and brain function. Neurobiol. Aging. 18:309-318.

    P. Green, R. Dawson Jr., D.R. Wallace and J. Owens. (1998). Treatment of rat brain membranes with taurine increases radioligand binding. Adv. Exp. Med. Biol. 442:377-383.

    D.R. Wallace, J. Owens and R.M. Booze. (1998). [3H](+) 7-OH-DPAT and [3H] Pramipexole binding in the striatum and nucleus accumbens of Sprague-Dawley and Fischer-344 rats. Life Sci. 63:PL275-PL280.

    L.C. Newman, D.R. Wallace and C.W. Stevens. (1999) Characterization of [3H]-diprenorphine binding in Rana pipiens: Observations of filter binding enhanced by naltrexone. J. Pharmacol. Toxicol. Meth. 41:43-48.

    A.L. Coon, D.R. Wallace and R.M. Booze. (1999) [3H] PN200-110 L-type calcium channel antagonist binding in the hippocampus and cerebellum of Alzheimer’s disease. Neurobiol. Aging. 20:597-603.

    D.R. Wallace and R.M. Booze. (2000) Sigma binding sites identified by [3H] DTG are elevated in aged Fischer-344 X Brown-Norway (F1) rats. Synapse. 35:311-313.

    L.C. Newman, D.R. Wallace, and C.W. Stevens. (2000) Selective opioid agonist and antagonist displacement of [3H]-Naloxone binding in amphibian brain. Eur. J. Pharmacol. 397:255-262.

    L.C. Newman, D.R. Wallace, and C.W. Stevens. (2000) Selective opioid agonist and antagonist competition for [3H] naloxone binding in the amphibian spinal cord. Brain Res. 884:184-191.

    L.C. Newman, D.R. Wallace, and C.W. Stevens. (2002) Binding characterization of selective opioids in Rana pipiens brain. J. Pharm. Exp. Therap. 301:364-370.

    G.N. Belofsky, A.F. French, D.R. Wallace, and S.L. Dodson (2004) New geranyl stilbenes from Dalea purpurea with in vitro opioid receptor affinity. J.Nat. Prod. 67:26-30.

    D.R. Wallace (2005) Overview of Molecular, Cellular and Genetic Neurotoxicology. Neurol Clin. North Amer. 23:307-320.

    G.N. Belofsky, D.R. Wallace, and S.L. Dodson (2005) Opioid receptor activity in Tall Grass Prairie plants traditionally used as for analgesia. J. Ethnopharm. (In Press).

    D.R. Wallace, S.L. Dodson, A. Nath, and R.M. Booze (2006) Delta opioid agonists attenuate TAT1-72-induced oxidative stress in SK-N-SH cells. Neurotoxicol. 27:101-107.

    D.R. Wallace, S. Dodson, A. Nath, and R.M. Booze (2006) Estrogen attenuates gp120- and tat1-72-induced oxidative stress and prevents loss of dopamine transporter function. Synapse. 59:51-60.

    J.M. Silvers, D.R. Wallace, S.B. Harrod, C.F. Mactutus, and R.M. Booze (2006) Prenatal cocaine alters dopamine and sigma receptor binding in nucleus accumbens and striatum in dams and offspring. Neurotox. Teratol. 28:173-180.

    R.M. Booze, D.R. Wallace, J.M. Silvers, B.J. Strupp, and C.F. Mactutus.  (2006) Prenatal cocaine exposure alters alpha-2 receptor expression in adolescent rats.  BMC Neuroscience 7:33.

    D.R. Wallace.  (2006)HIV Neurotoxicity: Mechanisms and potential protective mechanisms. J. Biomed Biotech. 2006:1-10.

    J. Zhu, C.F. Mactutus, D.R. Wallace and R.M. Booze (2009) HIV-1 Tat protein-induced rapid and reversible decrease in [3H] dopamine uptake: dissociation of [3H] dopamine uptake and [3H] WIN35,428 binding in rat striatal synaptosomes.  J. Pharmacol. Exp. Therap. 329:1071-1083.

    J.T. Curtis, A.N. Hood, Y. Chen, G.P. Cobb and D.R. Wallace (2010) Chronic metals ingestion by prairie voles produces sex-specific deficits in social behavior: An animal model of autism.  Behav Brain Res.  213:42-49.

    Instructional Activities

    • Medical Pharmacology - 2nd year medical students
    • BIOM 6543 Neurochemistry - Graduate Students
    • BIOM 6573 Neurotoxicology - Graduate Students
    • BIOM 6553 Neurochemical Basis of Disease - Graduate Students
    • VBSC 6200 Biochemical Toxicology - Graduate Students (Stillwater)
    • BIOM 6175 Molecular and Cellular Biology - Graduate Students

    Research Interests

    My laboratory has 3 major projects currently underway.  Project #1 examines the interaction between gp120/Tat (HIV proteins associated with neurotoxicity), estrogen, and cocaine in female rats. Ultimately, the goal of this research is to provide insight into gender-related differences in AIDS-related central nervous system disorders leading to potential gender-specific treatment strategies for HIV and cocaine addiction.  Project #2 examines the effects of low-level heavy metal exposure on the dopaminergic function in cell culture and whole animal. Low-level exposure to heavy metals may not cause overt CNS effects until much later. These studies have implications in forensic analysis and determining the potential cause of CNS damage.  Of major concern is that low-level exposure may also lead to the development of particular diseases of the CNS such as Autism.  Current work is also focusing on alterations in dopaminergic function following exposure to environmental toxins, such as heavy metals.  We have observed significant social dysfunction in male voles following exposure to mercury.  Neurochemical studies in rats have demonstrated that the striatum is a dopamine-rich brain region which is robustly affected following exposure to mercury.  Additional work is being performed to correlate the outcomes observed in rat and vole studies and to further examine the neurochemical alterations following mercury exposure.  Project #3 investigates the use of naturally occurring compounds as centrally acting agents. One series of studies has been examining the effects of Native American plants indigenous to Oklahoma and their potential analgesic effects. A second series is investigating the estrogenic effects of flavonoids found in soy and flaxseed.

    Biographical Information

    Dr. Wallace joined the University in 1996 after a 4 year fellowship at the University of Kentucky. Since his arrival, Dr. Wallace has been actively involved in teaching 2nd year medical students as well as graduate students in the Biomedical Science Program and the Forensic Science Program. Dr. Wallace has been extensively trained in basic pharmacological methods such as radioligand binding, neurotransmitter uptake/release and intracellular assays. The major foci and interests of the Wallace Laboratory are the excitatory mechanisms underlying neurotoxicity in the Central Nervous System.

OSU-CHS on Facebook OSU-CHS on Twitter OSU-CHS on Foursquare OSU Medicine on YouTube Google+